Axio Biosolutions Europe

Axio is a deep-science medical technology company with extensive expertise in biomaterials-based medical devices for pre-hospital, intra-operative and post-operative clinical needs. Our focus is on devices for the management of trauma, surgical and chronic wounds. Our flagship product, Axiostat, is a patented, clinically validated haemostat that stops moderate to severe bleeding instantly in surgeries and in pre-hospital trauma. Axiostat is USFDA 510(k) cleared and is also European CE approved. In the Advanced Wound Care range, Axio has launched the next-generation MaxioCel wound dressing. MaxioCel is designed to heal patients suffering from acute and chronic wounds (diabetic foot ulcers, pressure ulcers, burns, bed sores, cavity wounds and surgical site infections) by effectively managing exudates, pain reduction and scar-less healing. All Axio products are manufactured within ISO 13485 compliant and GMP-certified facilities.

• Employees 0
• Founded 2015